WASHINGTON, D.C. 20549
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
1.
|
|
Name of Reporting Persons. I.R.S. Identification Nos. of Reporting Persons (Entities Only)
|
|
|
Derma Medical Systems Inc.
|
|
|
|
2.
|
|
Check the Appropriate Box if a Member of a Group(See Instructions)
|
|
|
(a) [ ]
|
|
|
(b) [ ]
|
3.
|
|
SEC Use Only
|
|
|
|
|
4.
|
|
Citizenship or Place of Organization
|
|
|
|
|
|
Austria
|
Number of
|
|
5.
|
|
Sole Voting Power
|
Shares
|
|
|
|
2,023,423 shares of Common Stock
|
Beneficially
|
|
|
Owned by
|
|
6.
|
|
Shared
Voting Power
|
Each
|
|
|
|
0 shares of Common Stock
|
Reporting
|
|
|
Person
|
|
7.
|
|
Sole
Dispositive Power
|
With:
|
|
|
|
2,023,423 shares of Common Stock
|
|
|
|
|
|
|
|
8.
|
|
Shared
Dispositive Power
|
|
|
|
|
0 shares of Common Stock
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
|
|
2,023,423
|
|
|
|
10.
|
|
Check if the Aggregate Amount in Row (9) Excludes Certain
Shares (See Instructions)
|
|
|
|
|
|
|
11.
|
|
Percent of Class Represented by Amount in Row (9)
|
|
|
7.7%
|
|
|
|
12.
|
|
Type of Reporting Person (See Instructions)
|
|
|
CO
|
|
|
|
1.
|
|
Name of Reporting Persons. I.R.S. Identification Nos. of Reporting Persons (Entities Only)
|
|
|
Dr. Thomas Wenkart
|
|
|
|
2.
|
|
Check the Appropriate Box if a Member of a Group(See Instructions)
|
|
|
(a) [ ]
|
|
|
(b) [ ]
|
|
3.
|
|
SEC Use Only
|
|
|
|
4.
|
|
Citizenship or Place of Organization
|
|
|
|
|
|
Australia
|
Number of
|
|
5.
|
|
Sole Voting Power
|
Shares
|
|
|
|
2,423,423
|
Beneficially
|
|
|
Owned by
|
|
6.
|
|
Shared Voting Power
|
Each
|
|
|
|
0
|
Reporting
|
|
|
Person
|
|
7.
|
|
Sole Dispositive Power
|
With:
|
|
|
|
2,423,423
|
|
|
|
|
|
|
|
8.
|
|
Shared Dispositive Power
|
|
|
|
|
0
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
|
|
2,423,423
|
|
|
|
10.
|
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
|
|
|
|
|
|
11.
|
|
Percent of Class Represented by Amount in Row (9)
|
|
|
9.2%
|
|
|
|
12.
|
|
Type of Reporting Person (See Instructions)
|
|
|
IN
|
|
|
|
Item 1(a).
|
Name of Issuer
|
This Schedule 13G relates to the common stock, par value $0.001
per share (the “Common Stock”) of Targeted Medical Pharma, Inc. (the “Issuer”).
Item 1(b).
|
Address of the Issuer’s Principal Executive Offices
|
The Issuer’s principal executive office is located at 2980
Beverly Glen Circle, Suite 301, Los Angeles, CA 90077.
Item 2(a).
|
Name of Persons Filing
|
This Statement is filed on behalf of Derma Medical Systems Inc.
and Dr. Thomas Wenkart (the “Reporting Persons”).
Item 2(b).
|
Address of the Principal Business Office, or if none, Residence:
|
The address of the Reporting Persons is c/o Derma Medical Systems
Australia Pty Ltd - 301 Catherine Street Leichhardt NSW 2040 Australia.
Derma Medicals Systems Inc. is an American corporation and Dr. Wenkart
is an Australia citizen.
Item 2(d).
|
Title of Class of Securities
|
Common stock, par value $0.001 per share
876140104
Item 3.
|
If this statement is filed pursuant to Rules
13d-1(b)
, or
13d-2(b)
or (c), check whether the person filing is a:
|
Not applicable
|
(a)
|
[ ]
|
Broker or dealer registered under Section 15 of the Act.
|
|
|
|
|
|
(b)
|
[ ]
|
Bank as defined in Section 3(a) (6) of the Act.
|
|
|
|
|
|
(c)
|
[ ]
|
Insurance company as defined in Section 3(a) (19) of the Act.
|
|
|
|
|
|
(d)
|
[ ]
|
Investment company registered under Section 8 of the Investment Company Act of 1940.
|
|
|
|
|
|
(e)
|
[ ]
|
An investment
adviser in accordance with § 240.13d-1 (b) (1) (ii) (E).
|
|
|
|
|
|
(f)
|
[ ]
|
An employee benefit plan or endowment fund in accordance with § 240.13d-1 (b) (1) (ii) (F).
|
|
|
|
|
|
(g)
|
[ ]
|
A parent
holding company or control person in accordance with § 240.13d-1 (b) (1) (ii) (G).
|
|
|
|
|
|
(h)
|
[ ]
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
|
|
|
|
|
|
(i)
|
[ ]
|
A church plan that is excluded from the definition of an investment company under Section 3(c) 14 of the Investment Company Act of 1940.
|
|
|
|
|
|
(j)
|
[ ]
|
Group, in accordance with § 240.13d-1 (b) (1) (ii) (J).
|
(a) Amount
beneficially owned:
Derma Medical Systems Inc. beneficially owns 2,023,423 shares of
Common Stock. Dr. Wenkart beneficially owns 2,423,423 shares of Common Stock, 2,023,423 shares of which are held by Derma Medical
Systems Inc. and 400,000 shares of which are held by Ultera Pty Ltd ATF MPS Superannuation Fund.
Dr. Wenkart is the owner and President of Derma Medical Systems
Inc. and owner and Director of Ultera Pty Ltd ATF MPS Superannuation Fund.
(b) Percent of class:
Derma Medical Systems Inc. owns 7.7% of the class of Common Stock.
Dr. Wenkart owns 9.2% of the class of Common Stock.
(c)(1) Number of shares as to which Derma Medical Systems
Inc has.
(i) Sole
power to vote or direct the vote:
2,023,423 shares of Common Stock
(ii) Shared power to vote or direct the vote
Not Applicable
(iii) Sole power to dispose or direct the
disposition:
2,023,423 shares of Common Stock
(iv) Shared power to dispose or direct the
disposition of:
Not Applicable
(c)(2) Number of shares as to which Dr. Wenkart has:
(i) Sole power to vote or direct the vote:
2,423,423 shares of Common Stock
(ii) Shared power to vote or direct the vote
Not Applicable
(iii) Sole power to dispose or direct the
disposition:
2,423,423 shares of Common Stock
(iv) Shared power to dispose or direct the
disposition of:
Not Applicable
Item 5.
|
Ownership of Five Percent or Less of a Class
|
Not Applicable
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person
|
Not Applicable
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
|
Not Applicable
Item 8.
|
Identification and Classification of Members of the Group
|
Not Applicable
Item 9.
|
Notice of Dissolution of Group
|
Not Applicable
Not Applicable
SIGNATURE
After
reasonable inquiry and to the best of our knowledge and belief, I certify that the information set forth in this statement is
true, complete and correct.
April 9, 2014
|
|
|
Derma Medical Systems Inc.
|
|
|
|
|
By:
|
/s/
Dr. Thomas Wenkart
|
|
Name:
|
Dr. Thomas Wenkart
|
|
Title:
|
President
|
After reasonable inquiry and to the best of
our knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
April 9, 2014
|
|
|
|
/s/
Dr. Thomas Wenkart
|
|
Name:
|
Dr. Thomas Wenkart
|
Attention: Intentional misstatements or
omissions of fact constitute Federal criminal violations
(See 18 U.S.C. 1001)
EXHIBIT 1
JOINT FILING AGREEMENT
In
accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing
on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the common
stock, par value $0.001 per share, of Targeted Medical Pharma, Inc., and further agree that this Joint Filing Agreement shall
be included as an exhibit to such joint filings.
The
undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any
amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided,
however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such
party knows or has reason to believe that such information is inaccurate.
This
Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the
same instrument.
IN
WITNESS WHEREOF, the undersigned have executed this Agreement as of April 9, 2014.
|
Derma Medical Systems Inc.
|
|
|
|
|
By:
|
/s/
Dr. Thomas Wenkart
|
|
Name:
|
Dr. Thomas Wenkart
|
|
Title:
|
President
|
|
|
/s/
Dr. Thomas Wenkart
|
|
Name:
|
Dr. Thomas Wenkart
|